Clinical Trial Update: Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 trial of Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm after stem cell transplant was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastic Plasmacytoid Dendritic Cell Neoplasm

Drugs mentioned

• Elzonris (tagraxofusp)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2024-07-16